eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

CHOOSE ELIQUIS (apixaban) FOR YOUR PATIENTS
WITH DVT / PE

ELIQUIS – AN ORAL, DIRECT FACTOR XA INHIBITOR – IS INDICATED FOR:

Explore data for ELIQUIS in DVT / PE treatment and prevention

Treatment of DVT / PE

In the AMPLIFY clinical trial, ELIQUIS demonstrated both comparable efficacy with significantly less major bleeding vs. standard of care in the treatment of DVT / PE.2

Explore data from the AMPLIFY trial.

Extended treatment for prevention of recurrent DVT / PE

In the AMPLIFY-EXT clinical trial, ELIQUIS demonstrated superior efficacy with a comparable major bleeding profile vs. placebo for patients with DVT / PE.3

Explore data from the AMPLIFY-EXT trial.

Explore data for ELIQUIS in VTE prophylaxis after hip or knee surgery

In the ADVANCE-2 clinical trial, ELIQUIS demonstrated superior efficacy and a comparable bleeding rate
vs. enoxaparin in patients receiving treatment for prevention of VTE recurrence after elective total knee replacement surgery.4

Learn more about the ADVANCE-2 clinical trial.

In the ADVANCE-3 clinical trial, ELIQUIS demonstrated superior efficacy and a comparable bleeding rate
vs. enoxaparin in patients receiving treatment for prevention of VTE recurrence after elective total hip replacement surgery.5

Learn more about the ADVANCE-3 clinical trial.

Help protect your patients with DVT / PE

Diagnosemethoden

ELIQUIS dosing for your patients with DVT / PE is simple: START twice daily, STAY twice daily1

The approved indications for ELIQUIS are based on a robust clinical trial programme1

ELIQUIS is also available for your patients with NVAF1


Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

ADVANCE-2 = Apixaban Versus Enoxaparin for Thromboprophylaxis After Knee Replacement   
ADVANCE-3 = Apixaban Dosed Orally Versus Anticoagulation with Injectable Enoxaparin to Prevent Venous Thromboembolism   
AMPLIFY = Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line   
AMPLIFY-EXT = Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy–Extended Treatment   
DVT = Deep Vein Thrombosis   
NVAF = Non-Valvular Atrial Fibrillation   
PE = Pulmonary Embolism   
VTE = Venous Thromboembolic Events   

Not all patients who start on ELIQUIS for acute DVT / PE will stay on ELIQUIS; some acute DVT / PE patients who receive treatment do not require treatment for the prevention of recurrent DVT / PE. Other patients may be prescribed ELIQUIS for the prevention of recurrent VTE after initial treatment for acute DVT / PE with another anticoagulant.1 This is a decision for the prescribing clinician together with patient involvement in the decision-making.

References

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.
  2. Agnelli G et al. N Engl J Med 2013; 369: 799–808.
  3. Agnelli G et al. N Engl J Med 2013; 368: 699–708.
  4. Lassen MR et al. Lancet 2010; 375: 807–815.
  5. Lassen MR et al. N Engl J Med 2010; 363: 2487–2498.